glp 1 australia The role of GLP-1 receptor agonists in the management of obesity Australia officially entered its GLP-1

degludec assoc with: Liver fat content (LFC) 18-28% Both in either HbA1c or weight assoc with Both the visceral & subcutaneous abdominal fat equally ALT 4-22% AST 10-19% SURPASS-3 MRI trial (3/3) tirzepatide (particularly 10-15mg doses) looks to be possible treatments for #NAFLD #NASH, as well as #type2diabetes ongoing liver outcome RCT with liver biopsy clinicaltrials.gov/ct2/show/NCT04 SURPASS-3 CGM (1/2) another sub-study of SURPASS-3 (n=243) Dexcom G6 CGM used 1ry outcome - Time within Tight Target range 3.9-7.8 mmol/mol (71-140 mg/dL) at 24 + 52w % time within standard target range 3.9-10 mmol/mol (71-180 mg/dL) at 52w Presented by @TBattelino SURPASS - CGM (2/2) tirzepatide treatment assoc with: Marked in Tight TIR compared to ins

Dynamic Companies 45 11.5.4

Insulin GLP-1 RA Pen References: Pyrls, pyrls.com (Login required) Accessed 12/04/2025

Combining it with another incretin agonist compounds GI and hypoglycemia risk with no supporting evidence, so the documented protocol is monotherapy

Constipation indicates that GLP-1 is slowing your digestive system, which is part of its appetite-suppressing mechanism, but it is not a requirement for weight loss success